

FOI 3326

1st October 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Response:

Patients as of 11/09/25

Abatacept [Orencia]	88
Adalimumab [Humira]	24
Adalimumab Biosimilars	638
Apremilast [Otezla]	0
Baricitinib [Olumiant]	39
Bimekizumab [Bimzelx]	<5
Certolizumab [Cimzia]	78
Etanercept [Enbrel]	9
Etanercept Biosimilars	228
Filgotinib [Jyseleca]	0
Golimumab [Simponi]	73
Guselkumab [Tremfya]	16
Infliximab [Remicade]	<p>This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.</p> <p>Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.</p>
Infliximab Biosimilars	<p>This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this</p>

	<p>information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.</p> <p>Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.</p>
Ixekizumab [Taltz]	64
Risankizumab [Skyrizi]	<5
Rituximab [MabThera]	<p>This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.</p> <p>Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.</p>
Rituximab Biosimilars	<p>This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.</p> <p>Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.</p>
Sarilumab [Kevzara]	19
Secukinumab [Cosentyx]	161
Tocilizumab [Ro Actemra]	60

Tocilizumab Biosimilars	6
Tofacitinib [Xeljanz]	7
Upadacitinib [Rinvoq]	36
Ustekinumab [Stelara]	0
Ustekinumab Biosimilar	<5

Could you please provide the numbers of patients treated for Psoriatic Arthritis (PsA) ONLY in the last 3 months with the following drugs.

Response:

Abatacept [Orencia]	0
Adalimumab [Humira]	11
Adalimumab Biosimilars	223
Apremilast [Otezla]	0
Bimekizumab [Bimzelx]	<5
Certolizumab [Cimzia]	31
Etanercept [Enbrel]	<5
Etanercept Biosimilars	65
Golimumab [Simponi]	24
Guselkumab [Tremfya]	16
Infliximab [Remicade]	<p>This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.</p> <p>Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.</p>
Infliximab Biosimilars	<p>This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit)</p>

	<p>Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.</p> <p>Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.</p>
Ixekizumab [Taltz]	43
Risankizumab [Skyrizi]	<5
Secukinumab [Cosentyx]	97
Tofacitinib [Xeljanz]	<5
Upadacitinib [Rinvoq]	8
Ustekinumab [Stelara]	0
Ustekinumab Biosimilar	<5

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net